Saturday, October 04, 2025

 

Researchers discover air pollution particles hitching a ride around the body on red blood cells


But wearing a face mask reduces the threat



European Respiratory Society

pollution particles on red blood cells 

image: 

Representative light microscopy images of carbonaceous (black) particles adherent to red blood cells (red arrows) from healthy volunteers. Each image is from a different adult volunteer. 

view more 

Credit: ERJ Open Research





Researchers have found the first direct evidence that tiny particles of air pollution stick to our red blood cells, meaning they can travel freely around the body.

 

These particles are produced by vehicle exhausts and from brake and tyre wear, and can easily enter the lungs. They have recently been found in the brain and heart, where they are linked to increased risk of disease. However, until now, there has been no conclusive evidence of how pollution particles infiltrate these parts of the body.

 

In the new study, which is published in ERJ Open Research [1], researchers found an increase in pollution particles stuck to the red blood cells of healthy volunteers, after they spent time on a busy London road.

 

The research was by Professor Jonathan Grigg, Dr Norrice Liu and colleagues at Queen Mary University of London, UK.

 

The study involved 12 adult volunteers. Each volunteer spent four hours in an office building. Then they were asked to spend an hour within ten meters of a busy London road. They each carried a small device called an aethalometer, which measured the amount of particle pollution in the air around them. Then they returned to the office building for another hour.

 

Eight of the volunteers repeated the experiment on a different day, but this time wearing an FFP2 mask.

 

Researchers took blood samples from the volunteers after four hours in the office, immediately after their hour by the roadside and again after the hour back in the office. They used microscopes to take detailed photos of the blood samples, allowing them to see and quantify the pollution particles stuck to the red blood cells.

 

Levels of particle air pollution at the roadside were almost five times higher than in the office building, according to the aethalometers.

 

When researchers examined the blood samples, they found an increase in the amount of pollution particles stuck to volunteers’ red blood cells after they spent time by the roadside. On average, researchers found two to three times as much of the particle material stuck to people’s red blood cells after an hour by the road.

 

In some people, the levels decreased after an hour away from the road, while in others the levels remained high, suggesting there could be differences in how people’s bodies deal with the pollution they breathe in.

 

Although only a small proportion of red blood cells were carrying particles after exposure to roadside air pollution (around two or three out of every thousand), the researchers calculated that in the five litres of blood circulating in the human body, around 80 million red blood cells would be assumed to be transporting particles after standing near a main road for an hour.

 

When volunteers repeated the experiment wearing an FFP2 face mask, although they were exposed to the same levels of pollution by the roadside, the amount stuck on their red blood cells did not increase after standing by the road. Researchers say this is the first study to show that wearing an FFP2 mask reduces the dose of inhaled pollution particles in humans.

 

To confirm their findings, the researchers exposed human red blood cells and then mice to diesel exhaust particles in the lab. They found the particles stuck easily to both human and mouse red blood cells, and the more particles they added, the more they found stuck to the blood cells.

 

They also analysed some of the pollution particles they found on the volunteer’s blood cells and found that they contained iron, copper, silicon, chromium and zinc, which are known to be produced by vehicles exhaust, as well as silver, copper and molybdenum, which are produced by brake and tyre wear. The particles were 2.5 micrometres of smaller in size, corresponding to the PM2.5 measure used to monitor air pollution.

 

Professor Grigg said: “In our bodies, red blood cells work by collecting oxygen from our lungs and delivering it throughout the body. With this set of experiments, we have shown that tiny air pollution particles are hijacking our red blood cells, meaning they can also travel almost anywhere in the body.

 

“We’re finding more and more evidence that air pollution particles are making their way into many different organs of the body and now we have clear evidence of how that could be happening.

 

“This technique means we now have a relatively simple way to measure the amount of pollution entering the body, so now we can test out which factors might increase or reduce the problem. We were surprised to find how well an FFP2 face mask prevents these very tiny particles from reaching and attaching to blood cells.”

 

Professor Ane Johannessen is chair of the European Respiratory Society’s expert group on epidemiology and environment, based at the University of Bergen, Norway, and was not involved in the research. She said: “These tiny particles are produced by vehicles and industrial processes and released into the air we breathe. This study sheds light on how these dangerous particles might be infiltrating every part of the body via the bloodstream. It also suggests we could lower the risk with the right protective facemask. This could be beneficial for people who are vulnerable because they have a lung disease, or they cannot avoid spending time next to a busy road.

 

“However, most of us cannot avoid being exposed to dangerously high levels of air pollution in our daily lives, so we need laws to dramatically lower air pollution and reduce the risk for everyone.”

 

Alperujo storage times impact final compost yields



University of Córdoba

Storage of Alperujo influences composting performance: Insights into gaseous emissions and functional metagenomics 

image: 

researchers team

view more 

Credit: University of Cordoba





The UCO studied, for the first time, how alperujo storage times affect the subsequent composting process, taking into account both the quality of the product and the emission of greenhouse gases and microbiological activity

Alperujo is the main by-product of olive oil extraction. This waste presents a significant environmental challenge due to its high organic load and presence of phenolic compounds, which can contaminate soils and surface water. However, when the circular economy comes into play, alperujo can have a second life as a fertilizer, allowing the waste to be converted into a new product of value.

In order to better understand the composting process in which alperujo becomes a safe fertilizer for fields, the Molecular Biology of Stress Response Mechanisms and Waste Bioengineering: Green Engineering at the University of Córdoba groups joined forces to verify how a previously unstudied variable affects the composting process: alperujo storage times.

After oil extraction, the alperujo is stored in holding ponds until it undergoes treatment; in this case, composting to produce an organic fertilizer. "We studied how two different storage periods (3 and 6 months) affected the parameters during subsequent composting, such as yield, greenhouse gas emissions, the degradation of phenolic compounds, and the microbial community," explained Francisco Javier Ruiz, lead author of the study, together with Marina Barbudo.

After studying what happens on a real scale, the results showed that short-term storage (3 months) improves compost yields; that is, a greater amount of fertilizer is obtained. In addition, it generates lower greenhouse gas emissions during composting. "In both periods, phenolic compounds are efficiently removed, which is very important for the final product (the fertilizer) because these compounds are phytotoxic and can be harmful when applied in fields," said José Alhama, another of the authors. "The reason for the elimination mostly lies in the high temperature reached by the mass of compostable material, reducing the concentration of phenolic compounds and sanitizing the product," added researcher Maria del Carmen Gutiérrez.

Another innovation is the study of the microbial community during the process. "An innovation was analyzing the microbial community, identifying it taxonomically, and seeing its functional capacity. Linking this analysis to storage times was something that hadn't been evaluated," says researcher Maria Ángeles Martín Santos.

Metagenomic analysis revealed differences in the bacteriome of the raw material depending on its storage time, variations that also became evident during composting. "The thermophilic stage (the second phase of composting in which there is a great increase in temperature) prompted the selection of thermophilic bacteria (those that withstand high temperatures), which manage to degrade organic matter," continued Marina Barbudo.

According to Carmen Michán "this knowledge allows modifications to be made. If we know that a microorganism favors the degradation of certain compounds, if at any given time we don't want the final result to have, for example, a lot of phenols, it can help to add certain microorganisms." In this way, composting can be optimized. This study characterizes what happens at each juncture, allowing us to take advantage of or change conditions to obtain maximum yields with less environmental impact.

Reference:

Ruiz-Castilla FJ, Barbudo-Lunar M, Gutiérrez MC, Michán C, Martín MÁ, Alhama J. Storage of Alperujo influences composting performance: Insights into gaseous emissions and functional metagenomics. J Environ Manage. 2025 Aug 25;393:127015. doi: 10.1016/j.jenvman.2025.127015

 

Psilocybin targets brain circuits to relieve chronic pain, depression



Penn researchers offer new insights into psilocybin’s ability to break the pain-depression cycle




University of Pennsylvania School of Medicine





PHILADELPHIA— Researchers at Penn Medicine have identified specific brain circuits that are impacted by psilocybin—the active compound found in some psychedelic mushrooms—which could lead to new paths forward for pain and mental health management options. Chronic pain affects more than 1.5 billion people worldwide and is often deeply entangled with depression and anxiety, creating a vicious cycle that amplifies suffering and impairs quality of life. The study from the Perelman School of Medicine at the University of Pennsylvania- published today in Nature Neuroscience- offers new insight into ways to disrupt this cycle.

“As an anesthesiologist, I frequently care for people undergoing surgery who suffer from both chronic pain and depression. In many cases, they’re not sure which condition came first, but often, one makes the other worse,” said Joseph Cichon, MD, PhD, an assistant professor of Anesthesiology and Critical Care at Penn and senior author of the study. “This new study offers hope.  These findings open the door to developing new, non-opioid, non-addictive therapies as psilocybin and related psychedelics are not considered addictive.”

Targeting the Brain’s Pain and Mood Hub

In studies using mice with chronic nerve injury and inflammatory pain, researchers found that a single dose of psilocybin reduced both pain and pain-induced anxiety and depression-like behaviors, with those benefits lasting almost two weeks. Psilocybin acts by gently activating specific brain signals, called serotonin receptors (5-HT2A and 5-HT1A). “Unlike other drugs that fully turn these signals on or off, psilocybin acts more like a dimmer switch, turning it to just the right level,” said Cichon.

To pinpoint where the effects originated, researchers injected psilocin—the active substance into which the body converts psilocybin—into different regions of the central nervous system.  The team used advanced fluorescent microscopy, a technique that uses glowing dyes to see and capture neuronal activity, to see chronic pain neurons spontaneously firing. When psilocin was injected directly into the prefrontal cortex of the brain, specifically the anterior cingulate cortex (ACC), a part of the brain that processes pain and emotions, it provided the same pain relief and mood improvements as when psilocybin was given to the whole body.

 Researchers also injected psilocin into the spinal cord, but it didn’t have the same calming effect. “Psilocybin may offer meaningful relief for patients by bypassing the site of injury altogether and instead modulating brain circuits that process pain, while lifting the ones that help you feel better, giving you relief from both pain and low mood at the same time,” said Cichon.

Results Can Drive Future Psilocybin Research

Researchers believe the findings from this study could also inform therapies for other conditions involving dysregulated brain circuits, such as addiction or post-traumatic stress disorder. Cichon adds that more research is needed to determine the effectiveness of psilocybin. “In my anesthesiology practice, I often see that both pain and mood symptoms can worsen following surgery due to the physiological and psychological stress imposed by the procedure.  While psilocybin shows promise as a treatment for both pain and depression, it remains uncertain whether such therapies would be safe, effective, or feasible in the context of surgery and anesthesia,” adds Cichon. The Penn team plans to investigate optimal dosing strategies, long-term effects, and the ability of the brain to re-wire itself in sustaining these benefits in rodent models. “While these findings are encouraging, we don’t know how long-lived psilocybin’s effects are or how multiple doses might be needed to adjust brain pathways involved in chronic pain for a longer lasting solution,” adds Stephen Wisser, co-author and a Penn Neuroscience PhD student in Cichon’s lab.

The study was funded by the National Institutes of Health (R35GM151160-01) and the American Society of Regional Anesthesia and Pain Medicine (ASRA) Chronic Pain Medicine Research Award.

###

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System (UPHS) and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts,” Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines. 

The University of Pennsylvania Health System cares for patients in facilities and their homes stretching from the Susquehanna River in Pennsylvania to the New Jersey shore. UPHS facilities include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, chartered in 1751. Additional facilities and enterprises include Penn Medicine at Home, GSPP Rehabilitation, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff.


Aldous Huxley. (1894-1963). Page 2. Chapter One. A SQUAT grey building of only ... always soma, delicious soma, half a gramme for a half-holiday, a gramme ...


DECRIMINALIZE ALL DRUGS

Death toll from (WAR ON) drugs has more than doubled worldwide over past three decades


Deaths from drugs have increased two-fold since 1990, especially in high-income countries




Frontiers






Drug use disorder (DUDs), also called drug addiction, is the chronic and relapsing use of psychoactive substances in spite of considerable harm to the patient. The UN Office on Drugs and Crime has estimated that more than 250 million people around the world used illegal drugs at least occasionally in 2021, while 39.5 million people suffered from DUD.

But is this considerable global health burden increasing or decreasing? And what are the predicted trends for the near future? Now, a team of researchers from China has applied state-of-the-art statistical methods to find the answer to these questions. They have published their results in Frontiers in Psychiatry.

“We show that, while the number of new and existing cases of DUD changed little overall between 1990 and 2021, the number of drug-related deaths worldwide has more than doubled, and the total health loss has risen,” said Dr Ning Zhang, a professor at Jinshan Hospital of Fudan University in Shanghai, and the study’s corresponding author.

Zhang and colleagues analyzed records from the Global Burden of Disease Study, collected by the Institute for Health Metrics and Evaluation at the University of Washington in Seattle.

Fewer cases, but more death and disability

The results from their analyses showed that worldwide, the global incidence (that is, new cases per year) of DUD increased by 36% between 1990 and 2021, from 10 million to 13.6 million people. Over the same period, the global prevalence (that is, total cases) of DUD increased by 34% to 53.1 million people.

However, the world’s population also rose by 50% between 1990 and 2021. When the authors corrected for this increase, they found a relative reduction by 6% in the global prevalence rate of DUD, from 709.2 cases per 100,000 in 1990 to 663.8 cases per 100,000 people in 2021.

Despite this slight decline in prevalence rate, the global mortality rate due to drug use increased by 31%, from 1.3 deaths per 100,000 people in 1990 to 1.7 deaths per 100,000 people in 2021. The global number of deaths more than doubled over the same period, from 61,774 to 137,278 deaths per year.

Likewise, the global number of disability-adjusted life years (DALYs; a measure of the number of healthy life-years lost, due to death and disability) surged by 75% from 8.9 million years in 1990 to 15.6 million years in 2021.

The authors concluded that paradoxically, a slightly lower incidence of DUD in 2021 resulted in a much greater health burden around the world.

“The surge in deaths is mostly due to systemic gaps in harm reduction and access to treatment. It’s not necessarily new drugs, but the combination of potent substances like opioids and cocaine, along with worsening social and healthcare conditions for existing users, which is responsible,” said Zhang.

Burden greatest in most developed countries

In general, regions and countries with a high socio-economic index had greater incidences and prevalences of DUD and lost more lives and healthy life-years than those with a low socio-economic index. For example, high-income North America showed an 11.2-fold increase in drug-related deaths between 1990 and 2021, to 74,451 deaths in 2021. The highest prevalence of DUD occurred in the US, with 3,821.4 cases per 100,000 persons in 2021. In Western Europe, the prevalence increased by 7% to 1,201.2 cases per 100,000 persons over this period.

The authors found no evidence that these grim numbers will improve anytime soon.

“If current patterns continue, deaths will likely remain high – or rise further – in high-income settings unless overdose prevention, treatment coverage, and harm-reduction are rapidly scaled up,” said Zhang.

“Some middle-income regions may keep improving, but places with aging populations or economic stress could see worsening harms without targeted action.”